JP2023085370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023085370A5 JP2023085370A5 JP2023047018A JP2023047018A JP2023085370A5 JP 2023085370 A5 JP2023085370 A5 JP 2023085370A5 JP 2023047018 A JP2023047018 A JP 2023047018A JP 2023047018 A JP2023047018 A JP 2023047018A JP 2023085370 A5 JP2023085370 A5 JP 2023085370A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- combination
- agents
- agonizes
- contacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 101150013553 CD40 gene Proteins 0.000 claims 5
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000012830 cancer therapeutic Substances 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 238000009097 single-agent therapy Methods 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281571P | 2016-01-21 | 2016-01-21 | |
| US62/281,571 | 2016-01-21 | ||
| US201662301981P | 2016-03-01 | 2016-03-01 | |
| US62/301,981 | 2016-03-01 | ||
| JP2018538190A JP7026047B2 (ja) | 2016-01-21 | 2017-01-20 | 免疫調節剤を併用するがんの治療 |
| PCT/US2017/014375 WO2017127707A1 (en) | 2016-01-21 | 2017-01-20 | Treatment of cancer with combinations of immunoregulatory agents |
| JP2021196940A JP2022033899A (ja) | 2016-01-21 | 2021-12-03 | 免疫調節剤を併用するがんの治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021196940A Division JP2022033899A (ja) | 2016-01-21 | 2021-12-03 | 免疫調節剤を併用するがんの治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023085370A JP2023085370A (ja) | 2023-06-20 |
| JP2023085370A5 true JP2023085370A5 (enExample) | 2023-07-25 |
Family
ID=59360269
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538190A Active JP7026047B2 (ja) | 2016-01-21 | 2017-01-20 | 免疫調節剤を併用するがんの治療 |
| JP2021196940A Pending JP2022033899A (ja) | 2016-01-21 | 2021-12-03 | 免疫調節剤を併用するがんの治療 |
| JP2023047018A Pending JP2023085370A (ja) | 2016-01-21 | 2023-03-23 | 免疫調節剤を併用するがんの治療 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538190A Active JP7026047B2 (ja) | 2016-01-21 | 2017-01-20 | 免疫調節剤を併用するがんの治療 |
| JP2021196940A Pending JP2022033899A (ja) | 2016-01-21 | 2021-12-03 | 免疫調節剤を併用するがんの治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20170210803A1 (enExample) |
| EP (2) | EP4070812A1 (enExample) |
| JP (3) | JP7026047B2 (enExample) |
| KR (1) | KR102833922B1 (enExample) |
| CN (1) | CN109071676A (enExample) |
| AU (2) | AU2017210224B2 (enExample) |
| CA (1) | CA3011429A1 (enExample) |
| SG (1) | SG11201806110QA (enExample) |
| WO (1) | WO2017127707A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3011097C (en) | 2016-01-11 | 2022-12-20 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies |
| EP4194470A1 (en) * | 2017-10-18 | 2023-06-14 | Forty Seven, Inc. | Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 |
| PL4177270T3 (pl) * | 2017-10-18 | 2024-11-18 | Forty Seven, Inc. | Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47 |
| AR113862A1 (es) | 2017-12-01 | 2020-06-17 | Seattle Genetics Inc | Anticuerpos anti-cd47 y sus usos para tratar cáncer |
| WO2019109357A1 (zh) * | 2017-12-08 | 2019-06-13 | 杭州翰思生物医药有限公司 | 抗pd-1/cd47的双特异性抗体及其应用 |
| EP3752190B1 (en) | 2018-02-12 | 2022-07-06 | Forty Seven, Inc. | Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies |
| SG11202102851XA (en) | 2018-09-27 | 2021-04-29 | Celgene Corp | SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF |
| EP3860609A4 (en) * | 2018-10-01 | 2022-08-03 | Secura Bio, Inc. | COMBINATION THERAPIES |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN109517073A (zh) * | 2018-11-30 | 2019-03-26 | 北京泽勤生物医药有限公司 | 一种靶向治疗肿瘤的融合肽及其应用 |
| US20220056135A1 (en) * | 2018-12-21 | 2022-02-24 | Ose Immunotherapeutics | Bifunctional anti-pd-1/sirpa molecule |
| WO2020163692A1 (en) * | 2019-02-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway |
| CN113645980A (zh) * | 2019-03-08 | 2021-11-12 | 北卡罗莱纳州立大学 | 用于增强的免疫疗法的生物响应抗体复合物 |
| US20220288118A1 (en) * | 2019-07-31 | 2022-09-15 | Forty Seven, Inc. | Depletion regimes for engineered t-cell or nk-cell therapy |
| JP7369297B2 (ja) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用 |
| US20220251239A1 (en) * | 2020-10-22 | 2022-08-11 | Actinium Pharmaceuticals, Inc. | Combination radioimmunotherapy and cd47 blockade in the treatment of cancer |
| JP2023546679A (ja) * | 2020-10-22 | 2023-11-07 | アクティニウム ファーマシューティカルズ インコーポレイテッド | がん治療における放射免疫療法とｃｄ４７遮断の併用 |
| JP2024503822A (ja) * | 2021-01-05 | 2024-01-29 | ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン | Ｇｐｃ３及びｃｄ４７を標的とする二重特異性抗体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| SI2477648T1 (sl) * | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sinergijska terapija proti CD47 za krvne rake |
| KR20120107122A (ko) * | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질 |
| AU2011252851B2 (en) | 2010-05-14 | 2016-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to CD47 |
| US10238698B2 (en) * | 2012-01-25 | 2019-03-26 | Dnatrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| RU2693078C2 (ru) * | 2012-12-03 | 2019-07-01 | Новиммун С.А. | Анти-cd47 антитела и способы их применения |
| MX2015007446A (es) * | 2012-12-12 | 2015-12-07 | Vasculox Inc | Anticuerpos terapeuticos para cd47. |
| CN105189556A (zh) * | 2013-03-15 | 2015-12-23 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| WO2016023001A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| DK4186927T3 (da) * | 2015-10-21 | 2025-06-10 | Ose Immunotherapeutics | Fremgangsmåder og sammensætninger til at ændre makrofagers polarisering til pro-inflammatoriske celler til behandling af kræft |
| CN107459578B (zh) * | 2016-05-31 | 2021-11-26 | 泰州迈博太科药业有限公司 | 一种靶向cd47与pd-l1的双功能融合蛋白 |
-
2017
- 2017-01-20 AU AU2017210224A patent/AU2017210224B2/en active Active
- 2017-01-20 JP JP2018538190A patent/JP7026047B2/ja active Active
- 2017-01-20 KR KR1020187023116A patent/KR102833922B1/ko active Active
- 2017-01-20 US US15/411,623 patent/US20170210803A1/en not_active Abandoned
- 2017-01-20 CN CN201780018358.9A patent/CN109071676A/zh active Pending
- 2017-01-20 SG SG11201806110QA patent/SG11201806110QA/en unknown
- 2017-01-20 WO PCT/US2017/014375 patent/WO2017127707A1/en not_active Ceased
- 2017-01-20 EP EP22175627.3A patent/EP4070812A1/en active Pending
- 2017-01-20 CA CA3011429A patent/CA3011429A1/en active Pending
- 2017-01-20 EP EP17742028.8A patent/EP3405499A4/en not_active Ceased
-
2021
- 2021-04-08 US US17/225,668 patent/US20210230276A1/en not_active Abandoned
- 2021-12-03 JP JP2021196940A patent/JP2022033899A/ja active Pending
-
2023
- 2023-03-23 JP JP2023047018A patent/JP2023085370A/ja active Pending
-
2024
- 2024-05-02 AU AU2024202900A patent/AU2024202900A1/en active Pending
- 2024-11-06 US US18/939,377 patent/US20250066473A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Nanotechnology reprogramming metabolism for enhanced tumor immunotherapy | |
| An et al. | Nanoenabled disruption of multiple barriers in antigen cross-presentation of dendritic cells via calcium interference for enhanced chemo-immunotherapy | |
| Thorlund et al. | Landscape review of current HIV ‘kick and kill’cure research-some kicking, not enough killing | |
| JP2019506400A5 (enExample) | ||
| Shenoy et al. | Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models | |
| TWI733652B (zh) | 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑 | |
| Garg et al. | ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses | |
| US9717731B2 (en) | TEC family kinase inhibitor adjuvant therapy | |
| US20170071944A1 (en) | Modulators of toll-like receptors for the treatment of hiv | |
| TW202519526A (zh) | 二醯基甘油激酶調節化合物 | |
| KR20230011471A (ko) | Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물 | |
| KR20160066554A (ko) | 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료 | |
| JP2019503386A (ja) | 免疫療法を増強するためのヒストンデアセチラーゼ阻害剤の使用 | |
| RU2009107030A (ru) | Комбинированная терапия | |
| JPH09509136A (ja) | 免疫増強治療のための薬学的組成物 | |
| JP2014513722A5 (enExample) | ||
| Yavuz et al. | Pharmaceutical approaches to HIV treatment and prevention | |
| Lin et al. | (−)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer: Lin et al. | |
| JP2013526519A (ja) | アンチセンスオリゴヌクレオチドを含む医薬組成物およびそれを使用する方法 | |
| TW201034674A (en) | Uses of NK receptor antagonists | |
| Huang et al. | Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced‐killer cells in a murine lung carcinoma model | |
| Tong et al. | Post‐TTM Rebound Pyrexia after Ischemia‐Reperfusion Injury Results in Sterile Inflammation and Apoptosis in Cardiomyocytes | |
| US20240325532A1 (en) | Compositions, systems, and methods for treating cancer using tumor treating fields and chimeric antigen receptor (car)-immune cells | |
| CN121889150A (zh) | 小分子抗病毒剂的固体剂型及其用途 | |
| JP5986116B2 (ja) | 創傷を治癒または治療するための分子標的 |